RPTX — Repare Therapeutics Income Statement
0.000.00%
Last trade - 00:00- $61.33m
- -$91.46m
- $53.48m
- 49
- 60
- 32
- 44
Annual income statement for Repare Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0.135 | 7.6 | 132 | 51.1 | 53.5 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 54.4 | 116 | 152 | 167 | 147 |
| Operating Profit | -54.3 | -109 | -19.8 | -116 | -93.5 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -54.7 | -109 | -13.9 | -103 | -83.2 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -53.4 | -107 | -29 | -93.8 | -84.7 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -53.4 | -107 | -29 | -93.8 | -84.7 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -53.4 | -107 | -29 | -93.8 | -84.7 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -1.43 | -2.83 | -0.693 | -2.23 | -1.98 |